ReviewFrontiers in immunology2021
MSCs and Inflammatory Cells Crosstalk in Regenerative Medicine: Concerted Actions for Optimized Resolution Driven by Energy Metabolism.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 127 citations in OpenAlex.
- Promises and Perspectives of Mesenchymal Stromal Cells in Companion and Farm Animals.International journal of molecular sciences · 2026Review
- Review
- Mesenchymal stem Cells and Extracellular Vesicles in Bladder Dysfunction: Mechanisms and Translational Perspectives.Stem cell reviews and reports · 2026Review
- Review
- Agent-based modeling identifies multiple paths for inflammation resolution.Bioinformatics (Oxford, England) · 2026Article
- A Self-Oxygenating Wound-Adaptive Stem Cell Encapsulation Platform for Chronic Wound Repair.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- The Therapeutic Potential of Stem Cell Therapy for Doxorubicin-Induced Cardiotoxicity: A Narrative Review.Health science reports · 2026Article
- Mesenchymal Stem Cells and Extracellular Vesicles: Bridging the Translational Gap in Regenerative Medicine.International journal of molecular sciences · 2026Article
- Targeting Leukopoiesis: Pharmacological and Biotechnological Strategies for the Treatment of Leukopenia.Biomedicines · 2026Review
- Bridging Osteoimmunology and Regenerative Therapy: The Role of MSCs and Extracellular Vesicles.International journal of molecular sciences · 2026Review
- Stem cell dysfunction and rejuvenation strategies in ageing: emerging advances in regenerative medicine.Frontiers in cell and developmental biology · 2026Review
- Extracellular adenosine released by mesenchymal stromal cells from young hosts boosts the antimicrobial activity of neutrophils from aged hosts againstImmunotherapy advances · 2026Article
- Regenerative medicine approaches for the treatment of peripheral nerve injuries: progress and challenges.Regenerative biomaterials · 2026Review
- Peripheral blood-derived mesenchymal stem cells in osteochondral repair: a perspective on emerging insights and future directions.Frontiers in bioengineering and biotechnology · 2026Article
- Cell Surface Markers of Mesenchymal Stem Cells: Current Knowledge and Advances in Characterization Technologies.Life (Basel, Switzerland) · 2025Review
- Therapeutic and Diagnostic Roles of MSC-Derived Exosomes in Alzheimer's Disease.Brain and behavior · 2025Review
- Age-related evolution of human gingiva towards a fibrotic-like connective phenotype.Scientific reports · 2025Article
- Hanging drop culture reprograms mesenchymal stem cell transcriptome to enhance cell delivery efficiency via attenuated pulmonary entrapment.Drug delivery and translational research · 2025Article
- B cells induced regulatory T cells attenuated the classical M1 polarization of mouse bone marrow-derived macrophages.Scientific reports · 2025Article
- Therapeutic potential of human mesenchymal stromal cell-derived mitochondria in a rat model of surgical digestive fistula.Scientific reports · 2025Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stromal cells (MSCs) are currently widely used in cell based therapy regarding to their remarkable efficacy in controlling the inflammatory status in patients. Despite recent progress and encouraging results, inconstant therapeutic benefits are reported suggesting that significant breakthroughs in the understanding of MSCs immunomodulatory mechanisms of action remains to be investigated and certainly apprehended from original point of view. This review will focus on the recent findings regarding MSCs close relationship with the innate immune compartment, i.e. granulocytes and myeloid cells. The review will also consider the intercellular mechanism of communication involved, such as factor secretion, cell-cell contact, extracellular vesicles, mitochondria transfer and efferocytosis. Immune-like-properties of MSCs supporting part of their therapeutic effect in the clinical setting will be discussed, as well as their potentials (immunomodulatory, anti-bacterial, anti-inflammatory, anti-oxidant defenses and metabolic adaptation…) and effects mediated, such as cell polarization, differentiation, death and survival on various immune and tissue cell targets determinant in triggering tissue regeneration. Their metabolic properties in term of sensing, reacting and producing metabolites influencing tissue inflammation will be highlighted. The review will finally open to discussion how ongoing scientific advances on MSCs could be efficiently translated to clinic in chronic and age-related inflammatory diseases and the current limits and gaps that remain to be overcome to achieving tissue regeneration and rejuvenation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.